Home > Pipeline
Mablink focuses its efforts on cancers with high unmet medical needs and, to demonstrate the high potential of its proprietary PSARlink⢠technology, the first ADCs are addressing molecular targets for which they have already shown clinical promise.
Mablink is currently developing three ADC programs based on its proprietary linker, and exatecan (a topoisomerase I inhibitor) as the payload:
Discovery
Preclinical
Phase I
Phase II
Disc.
Precl.
Ph. I
Ph. II
Solid Tumors
Multiple Myeloma / Lymphomas
Acute Myeloid Leukemia